Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative intraperitoneal cisplatin after neoadjuvant chemotherapy for stage IIIC epithelial ovarian cancer
ISRCTN14782577Phase 2Completed
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Sep 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, paclitaxel and carboplatin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and serous peritoneal carcinoma (PPSC), sponsored by Institute of Oncology Ljubljana. Primary endpoints: Toxicity and Progression-free survival. Started Sep 2015; status: completed.
02
Drugs
cisplatinpaclitaxelcarboplatin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on ISRCTN14782577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14782577.